Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case.

Aged Antibodies, Monoclonal, Humanized / therapeutic use Carcinoma, Squamous Cell / drug therapy Female Humans Programmed Cell Death 1 Receptor / therapeutic use Skin Neoplasms / drug therapy
Case report Cemiplimab Cutaneous squamous cell carcinomas

Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
05 2022
Historique:
received: 25 03 2022
accepted: 26 03 2022
pubmed: 4 4 2022
medline: 4 5 2022
entrez: 3 4 2022
Statut: ppublish

Résumé

Cemiplimab, a monoclonal antibody directed against the PD-1 receptor of immune cells, has recent indication for the treatment of patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC). We present the clinical case of an elderly woman affected by locally advanced squamous carcinoma of the left cheek, in excellent response after only one course of therapy with cemiplimab, with good tolerability. Immunotherapy is a new therapeutic option in cSCC.

Identifiants

DOI: 10.1016/j.oraloncology.2022.105847 PMID: 35367788
pubmed: 35367788
pii: S1368-8375(22)00136-1
doi: 10.1016/j.oraloncology.2022.105847
pii:
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Programmed Cell Death 1 Receptor 0
cemiplimab 6QVL057INT

Types de publication

Case Reports Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

105847

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Antonio Ghidini (A)

Oncology Unit, Ospedale Giovanni Paolo II, Sciacca, AG, Italy. Electronic address: antonioghidini@hotmail.com.

Domenico Santangelo (D)

ORL Unit, Ospedale Giovanni Paolo II, Sciacca, AG, Italy.

Giovanni Vaccaro (G)

ORL Unit, Ospedale Giovanni Paolo II, Sciacca, AG, Italy.

Mario Chillura (M)

Oncology Unit, Medical Sciences Department, ASST Bergamo Ovest, Treviglio, BG, Italy.

Fausto Petrelli (F)

Oncology Unit, Casa di Cura Igea, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Cemiplimab in cutaneous squamous cell...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Cemiplimab in cutaneous squamous cell...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Tumeurs épidermoïdes › Carcinome épidermoïde › Cemiplimab in cutaneous squamous cell...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Cemiplimab in cutaneous squamous cell...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Récepteur-1 de mort cellulaire programmée › Cemiplimab in cutaneous squamous cell...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Tumeurs cutanées › Cemiplimab in cutaneous squamous cell...